Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...

Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...

Like in the STRIDE study of PAD, GLP-1s improved outcomes, but more work is needed to clarify who may benefit most.

India has officially approved and launched Mounjaro (tirzepatide), a groundbreaking injectable medication for the treatment of Type 2 diabetes and obesity. Developed by Eli Lilly and Company, the drug ...

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a leader in AI-powered drug discovery and biotherapeutics, today announced ...

A bipartisan group of congressional lawmakers is calling on the Trump administration to address the continued sale of illicit, compounded GLP-1 products, warning that consumers may be accessing ...

Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised ...

Lembas ( ), an AI-powered bioactive peptide discovery company, has emerged from stealth mode with a scientific breakthrough ...

Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I ...

Back-to-back studies map complementary hunger and satiety pathways, offering clues to refine weight-loss drugs.

In what Guggenheim Partners called one of Metsera’s “critical program milestones” this year, its ultra-long-acting amylin ...